The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m²

References

• International Diabetes Federation. IDF Diabetes Atlas, 7th Edition. 2015. Belgium http://www.idf.org/diabetesatlas. Accessed April 4, 2016
   Google Scholar
• Soriguer F, Goday A, Bosch-Comas A, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Diabetes Study. Diabetologia 2012;55:88-93
   PubMed Web of Science ®Google Scholar
• Almdal T, Scharling H, Jensen JS, et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004;164:1422-6
   PubMed Web of Science ®Google Scholar
• Roper NA, Bilous RW, Kelly WF, et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 2001;322:1389-93
   PubMed Web of Science ®Google Scholar
• Mata-Cases M, Casajuana M, Franch-Nadal J, et al. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain. Eur J Health Econ 2015;15:1-10
   Google Scholar
• Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 2015;385:2057-66
   PubMed Web of Science ®Google Scholar
• Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014;384:1349-57
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. A study comparing the effect of dulaglutide with liraglutide in type 2 diabetes (AWARD-6). Eli Lilly and Company; 2014. London, United Kingdom, https://clinicaltrials.gov/ct2/show/NCT01624259 Accessed Jan 15th 2016
   Google Scholar
• Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 2015;38:2241-9
   PubMed Web of Science ®Google Scholar
• Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-58
   PubMed Web of Science ®Google Scholar
• Umpierrez G, Povedano ST, Manghi FPr, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014;37:2168-76
   PubMed Web of Science ®Google Scholar
• Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014;37:2895
   Web of Science ®Google Scholar
• IMS. IMS MAT 2016 for Spain. IMS; United Kingdom, 2016. http://www.imspadds.com/midas/ IMS Health Data Accessed July 1, 2016
   Google Scholar
• Grant D, Foos V, Palmer J, et al. Long-term validation of the IMS CORE Diabetes Model in Type 1 and Type 2 diabetes. New Jersey, United States of America: Value in Health Journal, 1203-p
   Google Scholar
• Hornberger J. Computer modeling of diabetes and its complications: a report on the fifth mount hood challenge meeting. Value Health 2013;16:453-4
   PubMedGoogle Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27-S40
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Mount H. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value in Health 2013;16:670-85
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5-S26
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estadistica. Consumer Prices: All Items. 2014. Madrid, Spain http://www.ine.es/en/welcome_en html Accessed Nov 2014
   Google Scholar
• Lopez-Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 2010;11:513-20
   PubMed Web of Science ®Google Scholar
• World Health Organisation. WHO Report on the Global Tobacco Epidemic, 2013; Country profile Spain Geneva Switzerland: WHO Press. 2013
   Google Scholar
• World Health Organisation. World Health Organisation Country Statistics: Spain. Alcohol Consumption: Levels and Patterns. 2014 Geneva Switzerland: WHO Press
   Google Scholar
• NICE. Type 2 diabetes in adults: management. 2015. United Kingdom https://www.nice.org.uk/guidance/ng28 Accessed Jan 2016
   Google Scholar
• Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006;69:2057-63
   PubMed Web of Science ®Google Scholar
• Divino V, DeKoven M, Hallinan S, et al. Glucagon-like peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries. Diabetes Ther 2014;5:499-520
   PubMed Web of Science ®Google Scholar
• Levin PA, Wei W, Zhou S, et al. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes. J Managed Care Pharm 2014;20:501-12
   Google Scholar
• Beaudet A, Clegg J, Thuresson PO, et al. Review of utility values for economic modeling in type 2 diabetes. Value Health 2014;17:462-70
   PubMed Web of Science ®Google Scholar
• Brazier J. Measuring and valuing health benefits for economic evaluation. Toronto, Canada: Oxford University Press; 2007
   Google Scholar
• Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2011;12:219-30
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65
   PubMed Web of Science ®Google Scholar
• Consejo General de Colegios Oficiales de Farmaceuticos. BOTPlus. 2015. Madrid, Spain https://botplusweb portalfarma com/. Accessed November 27, 2015
   Google Scholar
• Spanish Government. Real Decreto-ley 8/2010. Madrid, Spain 2010. http://www.boe.es/boe/dias/2010/05/24/pdfs/BOE-A-2010-8228.pdf Accessed November 2014
   Google Scholar
• Guisasola A. Análisis de costes del tratamiento de la diabetes mellitus tipo 2 con insulina glargina o detemir. Av Diabetol 2010;26:430-5
   Google Scholar
• Farmacia Encasa. Farmacia Encasa. 2014. Madrid, Spain https://wwwfarmaciaencasaonline.es Accessed November 2014
   Google Scholar
• Owens D, Barnett A, Pickup J. Blood glucose self-monitoring in type 1 and type 2 diabetes: reaching a multidisciplinary consensus. Diabetes Primary Care 2004;6:8-19
   Google Scholar
• Consellería de Sanidade. Diario Oficial de Galicia n° 222, 21 noviembre 2012. Galicia, Spain 2012
   Google Scholar
• Departament de Salut. Diari Oficial de la Generalitat de Catalunya n° 6387. Catalonia, Spain 2013
   Google Scholar
• Departamento de Sanidad. Boletín Oficial del País Vasco 30 julio 2007 n° 145. Pais Vasco, Spain 2007
   Google Scholar
• Diario Oficial de Castilla- La Mancha n° 267. Servicio de Salud de Castilla-La Mancha (2008). Castilla- La Mancha, Spain 2008
   Google Scholar
• Goodall G, Costi M, Timlin L, et al. Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. Endocrinol Nutr (English edn) 2011;58:331-40
   PubMedGoogle Scholar
• Hernández-Pastor L. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration. Clin Ther 2008;30:2436-51
   PubMed Web of Science ®Google Scholar
• Mezquita-Raya P, Reyes-Garcia R, Moreno-Perez O, et al. Clinical effects of liraglutide in a real-world setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study. Diabetes Ther 2015;6:173-85
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad PSeI. Registro de altas. CIE9 MC – CMBD 2011. 2013. Madrid, Spain http://pestadistico.msc.es Accessed November 2014
   Google Scholar
• Osakidetza. Servicio Vasco de Salud. 2013. Pais Vasco, Spain http://www osakidetza euskadi.net/r85 Accessed November 2014
   Google Scholar
• Parra-Moncansi E, Arenas Jimenez MD, Alonso M, et al. Multicentre study of haemodialysis costs. Nefrologia 2011;31:299-307
   PubMed Web of Science ®Google Scholar
• Piñol C, Roze S, Valentine W, et al. [Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain]. Gac Sanit 2007;21:97-104
   PubMed Web of Science ®Google Scholar
• Ray JA, Valentine WJ, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005;21:1617-29
   PubMed Web of Science ®Google Scholar
• Schwander B, Gradl B, Zollner Y, et al. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe—the HEALTH model. Value Health 2009;12:857-71
   PubMed Web of Science ®Google Scholar
• World Health Organisation. WHO ATC/DDD Index 2015. Oslo, Norway: WHO; 2015. http://www.whocc.no/atc_ddd_index/. Accessed November 27, 2015
   Google Scholar
• Sacristan JA, Oliva J, del Llano J, et al. What is an efficient health technology in Spain? Gaceta Sanitaria 2002;16:334-43
   PubMedGoogle Scholar
• Mezquita-Raya P, Perez A, Ramirez de Arellano A, et al. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Ther 2013;4:417-30
   PubMed Web of Science ®Google Scholar
• Perez A, Mezquita-Raya P, Ramirez de Arellano A, et al. Cost-effectiveness analysis of incretin therapy for type 2 diabetes in Spain: 1.8 mg liraglutide versus sitagliptin. Diabetes Ther 2015;6:61-74
   PubMed Web of Science ®Google Scholar
• Raibouaa A, Borgeke H, Alexiou D, et al. Cost-effectiveness of dulaglutide 1.5 mg once weekly for the treatment of patients with type two diabetes mellitus in Sweden. Value Health J Int Soc Pharmacoecon Outcomes Res 2015;18:A607
   Google Scholar
• Foos V, Palmer JL, Grant D, et al. The IMS CORE diabetes model: model user guide. IMS Health. August 27. Basel, Switzerland http://www.core-diabetes.com/cdm.asp. Accessed April 1 2015
   Google Scholar